Literature DB >> 2598979

Nasal administration of glucagon and human calcitonin to healthy subjects: a comparison of powders and spray solutions and of different enhancing agents.

A E Pontiroli1, M Alberetto, A Calderara, E Pajetta, G Pozza.   

Abstract

The systemic availability of glucagon and human calcitonin given intranasally to healthy volunteers as spray solutions or powders has been examined. Glucagon was absorbed only when surfactants were used, and 9-lauryl ether (as a spray) and sodium glycocholate (as spray or powder) were equally active. Calcitonin was poorly absorbed when given alone but the surfactants dihydrofusinate (as spray or powder) and glycocholate (as a spray) were equally active in promoting absorption. Thus, enhancers are required to obtain significant nasal absorption of glucagon and calcitonin and powders and spray solutions did not differ in terms of systemic availability.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2598979     DOI: 10.1007/bf00558516

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

Review 1.  Alternative routes of peptide hormone administration.

Authors:  A E Pontiroli; A Secchi; M Alberetto
Journal:  Spec Top Endocrinol Metab       Date:  1985

2.  Intranasal calcitonin and plasma calcium concentrations in normal subjects.

Authors:  A E Pontiroli; M Alberetto; G Pozza
Journal:  Br Med J (Clin Res Ed)       Date:  1985-05-11

3.  Metabolic effects of intranasally administered glucagon: comparison with intramuscular and intravenous injection.

Authors:  A E Pontiroli; M Alberetto; G Pozza
Journal:  Acta Diabetol Lat       Date:  1985 Apr-Jun

4.  The effect of rectal and nasal administration of salmon calcitonin in normal subjects.

Authors:  T Buclin; J P Randin; A F Jacquet; M Azria; M Attinger; F Gomez; P Burckhardt
Journal:  Calcif Tissue Int       Date:  1987-11       Impact factor: 4.333

5.  Human insulin plus sodium glycocholate in a nasal spray formulation: improved bioavailability and effectiveness in normal subjects.

Authors:  A E Pontiroli; M Alberetto; E Pajetta; A Calderara; G Pozza
Journal:  Diabete Metab       Date:  1987 Jul-Aug

6.  Nasal absorption of insulin: enhancement by hydrophobic bile salts.

Authors:  G S Gordon; A C Moses; R D Silver; J S Flier; M C Carey
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

7.  1-Year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin.

Authors:  J Y Reginster; D Denis; A Albert; R Deroisy; M P Lecart; M A Fontaine; P Lambelin; P Franchimont
Journal:  Lancet       Date:  1987-12-26       Impact factor: 79.321

8.  Intranasal aerosolized insulin. Mixed-meal studies and long-term use in type I diabetes.

Authors:  R Salzman; J E Manson; G T Griffing; R Kimmerle; N Ruderman; A McCall; E I Stoltz; C Mullin; D Small; J Armstrong
Journal:  N Engl J Med       Date:  1985-04-25       Impact factor: 91.245

9.  Insulin administered intranasally as an insulin-bile salt aerosol. Effectiveness and reproducibility in normal and diabetic subjects.

Authors:  A C Moses; G S Gordon; M C Carey; J S Flier
Journal:  Diabetes       Date:  1983-11       Impact factor: 9.461

10.  Insulin given intranasally induces hypoglycaemia in normal and diabetic subjects.

Authors:  A E Pontiroli; M Alberetto; A Secchi; G Dossi; I Bosi; G Pozza
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-30
View more
  14 in total

Review 1.  Drug metabolism in the nasal mucosa.

Authors:  M A Sarkar
Journal:  Pharm Res       Date:  1992-01       Impact factor: 4.200

2.  Intranasal and intramuscular human calcitonin in female osteoporosis and in Paget's disease of bones: a pilot study.

Authors:  A E Pontiroli; E Pajetta; A Calderara; M Alberetto; G Pozza; V Manganelli; G Resmini; L Tessari; V Maresca
Journal:  J Endocrinol Invest       Date:  1991-01       Impact factor: 4.256

3.  Proteolysis of human calcitonin in excised bovine nasal mucosa: elucidation of the metabolic pathway by liquid secondary ionization mass spectrometry (LSIMS) and matrix assisted laser desorption ionization mass spectrometry (MALDI).

Authors:  S R Lang; W Staudenmann; P James; H J Manz; R Kessler; B Galli; H P Moser; A Rummelt; H P Merkle
Journal:  Pharm Res       Date:  1996-11       Impact factor: 4.200

4.  Letter to the Editor: Intranasal Glucagon for Hypoglycemia.

Authors:  Antonio E Pontiroli
Journal:  Curr Diab Rep       Date:  2017-01       Impact factor: 4.810

Review 5.  Intranasal drug delivery. Potential advantages and limitations from a clinical pharmacokinetic perspective.

Authors:  A E Pontiroli; A Calderara; G Pozza
Journal:  Clin Pharmacokinet       Date:  1989-11       Impact factor: 6.447

6.  Nasal insulin delivery with dimethyl-beta-cyclodextrin as an absorption enhancer in rabbits: powder more effective than liquid formulations.

Authors:  N G Schipper; S G Romeijn; J C Verhoef; F W Merkus
Journal:  Pharm Res       Date:  1993-05       Impact factor: 4.200

7.  Hypocalcemic effect of salmon calcitonin following single and repeated nasal and intravenous administration in young rabbits.

Authors:  N G Schipper; S G Romeijn; J Verhoef; F W Merkus
Journal:  Calcif Tissue Int       Date:  1994-01       Impact factor: 4.333

8.  In vitro nasal transport across ovine mucosa: effects of ammonium glycyrrhizinate on electrical properties and permeability of growth hormone releasing peptide, mannitol, and lucifer yellow.

Authors:  P M Reardon; C H Gochoco; K L Audus; G Wilson; P L Smith
Journal:  Pharm Res       Date:  1993-04       Impact factor: 4.200

Review 9.  Intranasal salmon calcitonin. A review of its pharmacological properties and potential utility in metabolic bone disorders associated with aging.

Authors:  S P Clissold; A Fitton; P Chrisp
Journal:  Drugs Aging       Date:  1991 Sep-Oct       Impact factor: 3.923

10.  Pharmacokinetics of intranasal, intramuscular and intravenous glucagon in healthy subjects and diabetic patients.

Authors:  A E Pontiroli; A Calderara; M G Perfetti; S R Bareggi
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.